Related posts

New Wall Street highs before tech earningsStocks fade, Bitcoin ETF false alarmMarkets hit 52-week highs
Investor Insights

This summary was created by AI, based on 4 opinions in the last 12 months.

Illumina Inc. has faced challenges such as missed quarters, a CEO resignation due to activist investor revolt, and reduced operating margin and EPS guidance. However, experts believe in its dominant market share, robust technology, and potential for significant EPS growth in the future. The company's strong cash flows and global exposure also position it well for the long term, despite recent issues.

Consensus
Mixed
Valuation
Fair Value
DON'T BUY
Illumina Inc.

It missed several quarters. Is down 43% this year, though up 4.1% today. Today's buyers are wrong.

Consumer Products
BUY ON WEAKNESS
Illumina Inc.
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

The CEO was a victim of the shareholder activist revolt, and the lawsuits are not material in any way, in our view (in fact, one doesn't even use the right company name, having copy/pasted from another lawsuit). We do think the company's dominant market share and robust technology win win out in the end. EPS (adjusted), based on consensus is expected to nearly triple next year. We are also encouraged that ILMN in 2017 received a takeover offer (from Thermo Scientific) at about 40% higher than current levels. Since then sales have nearly doubled and it has been very profitable (except for a loss expected this year). 
Unlock Premium - Try 5i Free

Consumer Products
HOLD
Illumina Inc.
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

ILMN has been 'distracted' with its fight with activist investors, and its CEO has resigned as fall-out. But we think this is largely reflected in the price now. Illumina will need to regain trust in its ability to deliver on its longer-term goals after initial 2023 guidance for operating margin and EPS fell far short of consensus, which has since been taken down even further. Expectations may have been too frothy after Illumina announced new products and a solid longer-term financial framework at its Genomics Forum and investor day. The reduced outlook accounts for issues in China and the ramping up of its NovaSeq X launch, on top of depressed spending. Consolidated operating margin is forecast at 5% with Grail's dilution, vs. 20% for the core businesses. Top line sales rose just 1% in 2022 after generating an outsized 40% gain in 2021, and is expected to remain flat in 2023. Other components modest pressure from currency. All-in, not so great. But considering its strong market share, global exposure and solid history, we think it deserves a few more quarters. This year has been most unusual. EPS is expected to nearly triple over the next two years, and this (if it occurs) should get things going again. 
Unlock Premium - Try 5i Free

Consumer Products
COMMENT
Illumina Inc.

80% of the world's genomic sequencing equipment runs on their machines. Strong cash flows, but earnings are a mess because they are spending on a big acquisition. But they have increased the board, which is good, and the company is well-positioned. The CEO resigned a few weeks ago and there's infighting about that acquisition.

Consumer Products
BUY
Illumina Inc.
They've had execution issues, but their products are top-notch. It's a takeover candidate when shares get cheap enough. But the FTC is hostile to mergers now.
Consumer Products
PARTIAL BUY
Illumina Inc.
Not for the feint of heart. They had a terrible year, but catalysts are coming, including an analysts' day in early October. There will be a decision on the merger with Grail. If the EU blocks it, Illumina will spin it out and that will be a big catalyst.
Consumer Products
PAST TOP PICK
Illumina Inc.
(A Top Pick Jun 11/21, Down 58%) Company still growing in double digits. New M&A has yet to be recognized by market. Waiting to see whether there is valuation compression or whether fundamental problem with company. Will continue to hold shares in company.
Consumer Products
BUY
Illumina Inc.
Stock price is priced low due to litigation problems & recent selloff in tech. Management has guided 14-16% revenue growth. Worried that there is no floor on how far the stock price can fall. Believes company will continue to grow, and has strong products.
Consumer Products
TOP PICK
Illumina Inc.

Global leader in DNA sequencing. Almost 90% recurring revenue with good growth. Highly cash generative with good balance sheet. Good acquirer. Expects DNA sequencing will be a pervasive treatment option in healthcare. (Analysts’ price target is $404.80)

Consumer Products
STRONG BUY
Illumina Inc.
They're the global leader in DNA sequencing. It's had a huge run though come back a bit. It enjoys long-term technical support.
Consumer Products
PAST TOP PICK
Illumina Inc.

(A Top Pick Sep 12/19, Up 6%) The sector is interesting, though he sold Illumina, because the holding got too big. They supply testing machines for mines, which creates recurring revenues. Stick with it.

Consumer Products
TOP PICK
Illumina Inc.
They are a provider of sequencing solutions for genetic analysis. It is a really good entry level. It is a pretty volatile stock. Commercial genetic testing is going to explode and these guys are emphasizing consumables. (Analysts’ price target is $321.79)
Consumer Products
PAST TOP PICK
Illumina Inc.
(A Top Pick Jul 18/18, Up 15%) They analyze genetic material. We are in the early stages of doing this for a whole host of applications. They are a generation ahead of competitors. This is a technology that is still relatively new.
Consumer Products
TOP PICK
Illumina Inc.
The DNA revolution has recently started. DNA sequencing has come from the thousands of dollars to the hundreds making it ore retail. Fast growing US name. (Analysts’ price target is $345.93)
Consumer Products
TOP PICK
Illumina Inc.

He is a big believer in disrupter companies in growth sectors. This is the only company in the world that can do high volume DNA sequencing. They already have a million customers and another million order backlog. There is no one else in this space. They sell equipment and the supplies to operate the equipment. Countries will have more DNA sequencing done to help new drug development. Yield 0%. (Analysts’ price target is $286.06)

Consumer Products
Showing 1 to 15 of 16 entries

Illumina Inc.(ILMN-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 3

Stockchase rating for Illumina Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Illumina Inc.(ILMN-Q) Frequently Asked Questions

What is Illumina Inc. stock symbol?

Illumina Inc. is a American stock, trading under the symbol ILMN-Q on the NASDAQ (ILMN). It is usually referred to as NASDAQ:ILMN or ILMN-Q

Is Illumina Inc. a buy or a sell?

In the last year, 3 stock analysts published opinions about ILMN-Q. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Illumina Inc..

Is Illumina Inc. a good investment or a top pick?

Illumina Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Illumina Inc..

Why is Illumina Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Illumina Inc. worth watching?

3 stock analysts on Stockchase covered Illumina Inc. In the last year. It is a trending stock that is worth watching.

What is Illumina Inc. stock price?

On 2024-04-19, Illumina Inc. (ILMN-Q) stock closed at a price of $117.43.